Press release archive
Browse GSK's global press release archive for media and investors. Search by keyword or browse by year/business category.
Press releases issued by our local operating companies can be viewed on our market websites.
-
Blenrep shows significant overall survival benefit, reducing the risk of death by 42% in multiple myeloma at or after first relapse
DREAMM-7 trial shows sustained overall survival benefit for Blenrep (belantamab mafodotin) combination versus daratumumab combination
Download (PDF, 231.4KB) -
US FDA accepts GSK’s submission for the use of Nucala (mepolizumab) in COPD
Nucala could be the first approved biologic with monthly dosing for patients with COPD
Download (PDF, 188.3KB) -
Blenrep (belantamab mafodotin) combination accepted for priority review in China in relapsed/refractory multiple myeloma
Regulatory submission supported by phase III head-to-head DREAMM-7 trial showing statistically significant efficacy.
Download (PDF, 140.2KB) -
GSK and Zhifei revise and extend strategic vaccine collaboration in China
Shingrix collaboration extended to 2034
Download (PDF, 233.8KB) -
First single-dose medicine for P. vivax malaria prequalified by WHO and included in WHO Guidelines
Important steps to advance access to first single-dose malaria treatment
Download (PDF, 164.0KB) -
GSK’s fully liquid Menveo meningococcal vaccine approved by European Commission
Formulation supports simplification of vaccination process against invasive meningococcal disease (IMD).
Download (PDF, 172.3KB) -
Blenrep combinations accepted for review by the US FDA for the treatment of relapsed/refractory multiple myeloma
Regulatory submission supported by phase III head-to-head DREAMM-7 and DREAMM-8 trials showing statistically significant efficacy.
Download (PDF, 147.9KB) -
Arexvy approval expanded to adults aged 50-59 at increased risk of severe RSV disease in Japan
First RSV vaccine approved in Japan to help protect 50-59 year olds at increased risk due to certain underlying health conditions.
Download (PDF, 141.3KB) -
Statement: GSK continues to show strong leadership in its Access to Medicines Index ranking
GSK is pleased to rank 2nd in the Access to Medicine Index (ATMI) in its ninth wave.
Download (PDF, 123.5KB) -
Linerixibat shows positive Phase III results in cholestatic pruritus (relentless itch) in primary biliary cholangitis (PBC)
Primary endpoint met with a statistically significant improvement in itch over 24 weeks compared with placebo
Download (PDF, 174.0KB) -
Blenrep shows overall survival benefit in head-to-head DREAMM-7 phase III trial for relapsed/refractory multiple myeloma
Full data to be presented at 2024 American Society of Hematology Annual Meeting in December.
Download (PDF, 139.7KB) -
GSK highlights key data from hepatology portfolio at the AASLD’s The Liver Meeting® 2024, emphasising patient impact in areas of high unmet need
New data shows potential for sequential therapy of bepirovirsen after daplusiran/tomligisiran to further increase functional cure rates.
Download (PDF, 279.3KB) -
New GSK-sponsored survey reveals unique gaps in care and support facing patients with gynaecologic cancers
GSK’s Your Cancer Is Our Challenge will raise awareness of barriers and inspire future solutions to address them, beyond treatment.
Download (PDF, 163.3KB) -
GSK on track to deliver 2024 outlooks with further good progress made in R&D
Q3 2024 performance highlights
-
GSK enters agreement to acquire CMG1A46 from Chimagen Biosciences to expand immunology pipeline
Agreement reinforces GSK’s portfolio in the treatment of lupus and underlying drivers of autoimmune disease
Download (PDF, 134.6KB) -
New data for Arexvy, GSK’s respiratory syncytial virus vaccine, show potential to help protect a broader group of adults at increased risk for RSV disease
Single dose of vaccine elicited robust immune response with acceptable safety profile in adults aged 18-49 at increased risk for RSV-LRTD.
Download (PDF, 244.1KB) -
GSK and Cambridge University announce new five-year collaboration in kidney and respiratory disease
GSK is investing more than £50 million in the CG-TIC to further accelerate research and development in kidney and respiratory diseases.
Download (PDF, 128.8KB) -
ViiV Healthcare shows more than 99% effectiveness in real-world studies for Apretude (cabotegravir long-acting), the only approved long-acting HIV PrEP, in data presented at IDWeek 2024
Studies from OPERA and Trio cohorts provide further real-world evidence.
Download (PDF, 271.8KB) -
Gepotidacin accepted for priority review by US FDA for treatment of uncomplicated urinary tract infections in female adults and adolescents
Gepotidacin could be the first in a new class of oral antibiotic treatment for uUTIs in over 20 years.
Download (PDF, 206.3KB) -
GSK announces positive phase III results from ANCHOR trials for depemokimab in chronic rhinosinusitis with nasal polyps
Depemokimab is an ultra-long-acting biologic administered once every six months
Download (PDF, 199.1KB)
